KEY TAKEAWAYS
- The study aimed to investigate the clinical practice treatment patterns and efficacy of front-line and 2L therapies in MCL.
- Researchers observed that front-line treatments were effective with a median PFS over 3.5 years.
There are few reports of clinical practice treatment patterns and efficacy in mantle cell lymphoma (MCL). This study aimed to fill this gap by analyzing treatment approaches and outcomes in a multicenter cohort of patients with MCL.
Minna Harmanen and the team aimed to assess the real-world effectiveness of front-line and second-line (2L) therapies, documenting their impact on progression-free survival (PFS).
They performed an inclusive analysis of a large, multicenter cohort of patients with MCL diagnosed between 2000 and 2020 across 8 institutions. Patient data were retrospectively reviewed to evaluate treatment patterns and outcomes.
About 536 patients were registered (73% male, median age of 70 years). Front-line treatment included high-dose cytarabine, bendamustine, and anthracyclines in 42%, 12%, and 15% of cases, respectively. The median PFS for all patients was 45 months; specific median PFS values were 68, 34, and 30 months for those receiving high-dose cytarabine-based, bendamustine-based, and anthracycline-based therapies, respectively.
Of the 204 patients who received 2L treatment, bendamustine-based regimens were the most common, accounting for 36% of cases. The median 2L PFS (sPFS) for the entire cohort was 14 months; for bendamustine-, platinum-, and high-dose cytarabine-based regimens, median sPFS was 19, 24, and 31 months, respectively, though these estimates had broad confidence intervals. Patients treated with cytarabine-based therapies in the front line and those with a front-line PFS longer than 24 months exhibited a significantly superior sPFS.
The study concluded that front-line treatment for MCL met expectations, demonstrating a median PFS of over 3.5 years. In contrast, 2L treatment strategies were varied, with a median 2L PFS of just over 1 year. These findings highlight the effectiveness of front-line therapies and underscore the need for more consistent and effective 2L treatment approaches.
The study was funded by the Savo Cancer Fund.
Source: https://pubmed.ncbi.nlm.nih.gov/38661269/
Harmanen M, Sorigue M, Khan M, et al. (2024). “Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.” Eur J Haematol. 2024 Aug;113(2):218-226. doi: 10.1111/ejh.14219. Epub 2024 Apr 25. PMID: 38661269.
